Anticoagulant treatment patterns and thromboembolic events by tumor type among patients with VTE and cancer

Abstract Background Patients with venous thromboembolism (VTE) and cancer are at higher risk of adverse outcomes (mortality, recurrent VTE etc.) versus patients alone; as such, clinical guidelines recommend anticoagulant treatment for cancer. There is limited real world data about how thromboembolic differ by tumor type in Understanding such differences may help identify appropriate specific types. Purpose To describe patterns among Methods age ≥65 were identified from the Surveillance, Epidemiology End Results (SEER) Medicare database 1/1/2014–12/31/2019. required to be enrolled ≥6-months prior their first diagnosis (index) without evidence other conditions requiring (i.e., atrial fibrillation) index. Cancer status SEER or 6-months through 30-days post VTE. This analysis focused on following types: high (brain, pancreas, stomach) common types (breast, prostate). treated an within after index included final population. Major bleeding (MB) events measured during follow-up (index date earliest disenrollment, death 12/31/2019). A total 3,546 anticoagulated interest met all study criteria (breast [n=1,197], prostate [n=849], pancreatic [n=995], brain [n=248] stomach [n=257] cancer). Patient mean ranged 73 (brain) 76 (stomach) Anticoagulant varied (Figure 1). LMWH was more likely used 3 whereas apixaban rivaroxaban 2 The incidence rate major also different ranging 1.4 (breast) 6.4 (pancreatic) per 100 person-years 4.3 (prostate) 15.1 2). Conclusion notable variations patters risks Further research needed understand which option type. Funding Acknowledgement Type funding sources: Private company. Main source(s): Pfizer Inc. Bristol Myers Squibb Company